Independent Panthera Biopartners appoints Stuart Young as CEO as the company further strengthens its team.

Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Stuart Young as chief executive. Stuart who was previously UK Country Manager of Synexus will lead the organisation’s expansion across the UK and into Europe. Panthera which opened its first clinical trial site in Preston, in the NW of England, late last year now has a full management team in place.

Stuart previously managed the UK division of Synexus overseeing nine dedicated research sites. Stuart is particularly focussed on the use of technology to reduce costs in clinical trials, provide a first rate patient experience and ensure that Panthera is at the cutting edge of clinical research. Stuart, who holds a degree in Mechanical Engineering from University of Strathclyde in Glasgow has had extensive experience in data management and the introduction of new technologies into organisations.

Stuart joins Chairman, Chief Financial Officer and co-founder Professor John Lyon, who was previously a global executive in CRO Covance; Medical Director and co-founder Dr Ian Smith, who previously founded Synexus and Jane Restorick, Chief Commercial Officer, who was most recently Chief Operating Officer and Chief Patient Officer at Synexus.

Stuart commented  ”I am delighted to join such an experienced team. Our collective expertise in running clinical trials across the globe is second to none. While we are just starting our journey we are already on target to open more sites in the UK; we are in discussions on expanding across Europe; and most importantly as an independent organisation with a world class team we have been received very warmly by both CROs and pharma.”

Chairman John Lyon, “We are really pleased to welcome Stuart as CEO of Panthera. Not only does he know the clinical trial business inside out he has the understanding and technical knowledge to ensure that Panthera is a world leader in the introduction of technology into all aspects of recruiting patients, running and reporting on clinical trials.”

Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, diabetes. etc. It will also expand into other key indications including neurology and oncology.

The company opened its first clinical trial site in Preston, Lancashire, UK in November 2019. The clinical trial site, which is the first of a number of planned across the UK and overseas, is already involved in implementing trials on behalf of its clients from CROs and pharma companies.

Panthera Biopartners – an Independent Site Management Organisation

Panthera Biopartners was founded by Dr Ian Smith – founder of Synexus - and Professor John Lyon – previously senior executive in Covance – to provide CROs and pharma clients with services relating to the recruitment and running of clinical trials at customised clinical trial sites by GCP trained healthcare professionals.

The first Panthera site was opened in Preston, Lancashire, UK in November 2019. Further sites are planned across the UK. Panthera is initially focused on therapeutic areas traditionally managed in primary care.

https://panthera-bio.com/